Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.10 1.22% 8.30 0.00 08:00:01
Bid Price Offer Price High Price Low Price Open Price
8.10 8.50 8.30 8.30 8.30
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.57 -0.96 13
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 8.30 GBX

N4 Pharma (N4P) Latest News

More N4 Pharma News
N4 Pharma Investors    N4 Pharma Takeover Rumours

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
22/6/202114:59N4 Pharma3,576
20/5/202108:25N4 Pharma - Making good drugs better.4,391
14/9/202007:40N4P Covid-19 Wealth Warning108

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

DateSubject
24/6/2021
09:20
N4 Pharma Daily Update: N4 Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 8.20p.
N4 Pharma Plc has a 4 week average price of 8.15p and a 12 week average price of 7.70p.
The 1 year high share price is 15.50p while the 1 year low share price is currently 3.85p.
There are currently 156,080,349 shares in issue and the average daily traded volume is 468,179 shares. The market capitalisation of N4 Pharma Plc is £12,798,588.62.
07/6/2021
10:23
machinist: Sold one of my lame ducks and topped up here. Got a good feeling about N4P which usually means it will dive now lol
26/5/2021
14:21
davethechef: Looks like they are 'playing with the share price'. Can't buy even tiddly amounts once again. Positive sign.
21/5/2021
10:13
alloa2003: Must admit I thought yesterday was the start of a gradual increase in the share price - seems we will have to wait a little longer to shake out the sellers.
20/5/2021
08:08
hamidahamida: https://twitter.com/mylesmcnulty/status/1395274111946043393?s=21At long last! @n4pharma #N4P has entered into two collaborations for its pDNA /mRNA delivery platform, Nuvec.One is with a "major international company working in the gene therapy space."I'd bet it's one of the mRNA giants, @moderna_tx $MRNA or @BioNTech_Group $BNTX. 1/5
17/5/2021
14:21
stockt2: Wouldn't move a penny from N4P won't get much better risk reward anywhere else.
17/5/2021
13:05
alloa2003: Why you ramping SYME on a N4P board?
12/5/2021
16:52
blueblood: Ordinary months or Nigel's N4P months.....
09/3/2021
11:07
gordan ghetto: ANA is the best UK cannabis stock Share price 1.1p Only £6.4m mkt cap Fastest growing sector worldwide Will have first mover advantage in UK Same growers as GW Pharma 4 biggest shareholders hold over 50% BOD own 30% Massively undervalued (£6.4m mkt cap) Near term multi bagger on license approval Partners with leading prof , scientists etc Primed for a RTO/ main listing (price driver) Under the radar (most chased MXC,CBX) Looking to bring a product to market Off take agreement in place already Will be producing 200 TONS per year (200,000 kilos) Has the most land out of every cannabis co Fully funded for phase 1 UK medical cannabis growing 20% month Only 584m shares in issue Hardly any available in open market Will apply for a commercial license too Worth getting in on the ground floor imho. hTTps://businesscann.com/work-on-12m-medicinal-cannabis-cultivation-facility-held-up-by-covid-19-uk-travel-ban/ hTTps://anandadevelopments.com/tiamat-agriculture-ltd/
09/12/2020
08:18
jakleeds: 09/12/2020 8:10am UK Regulatory (RNS & others) TIDMN4P RNS Number : 0543I N4 Pharma PLC 09 December 2020 9 December 2020 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 ("MAR"). In addition, market soundings (as defined in MAR) were taken in respect of the Placing with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR. This inside information is set out in this announcement. Therefore, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities. N4 Pharma plc ("N4 Pharma" or the "Company") Placing to raise GBP2 million N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to announce that it has raised GBP2 million (before expenses) through a placing of 25,000,000 new ordinary shares of 0.4p each in the Company (the "Placing Shares") at an issue price of 8p per Placing Share (the "Placing"). The Placing, which was significantly oversubscribed, was undertaken by share price Angel Corporate Finance LLP. The net proceeds of the Placing will be used for: -- the extension of the formulation and current stability work covering DNA and mRNA formulations; -- research on and evaluation of an additional asset to add to the Company portfolio; -- business development driven by study results pending over next six months; and -- ongoing working capital. Nigel Theobald, Chief Executive of N4 Pharma, commented: "We are delighted with the positive response to our recent formulation work. With vaccines and their delivery very much in the public consciousness we continue to grow our data package to present Nuvec(R) as a viable delivery technology solution to improve the delivery, storage and transportation of multiple existing and new vaccines. "Whilst we are well funded for all existing work streams these additional funds will enable us to plan for follow on studies and more product focussed experiments as we move towards collaborations." Application for Admission The Placing has been conducted utilising the Company's existing share authorities. Application has been made for the Placing Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on or around 14 December 2020. Once issued, the new Ordinary Shares will rank pari passu with the Company's existing ordinary shares. Total Voting Rights Following Admission, the enlarged issued share capital of the Company will comprise 181,080,349 Ordinary Shares of 0.4 pence each. The Company does not hold any ordinary shares in treasury. Consequently, 181,080,349 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
19/5/2020
10:37
jonc: !FOLLOWFEED Buying N4P might damage your wealth. However it is a Covid-19 outsider developing a novel delivery system for Covid-19 vaccines.. News is anticipated. Serious research is not required but would be welcomed. The N4P share price has retreated from highs of 32p and could retest on encouraging development news. Widows and Orphans not required. Ramping only please.
N4 Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
N4P
N4 Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 07:15:54